Advanced

Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.

Alkner, Sara LU ; Bendahl, Pär-Ola LU ; Fernö, Mårten LU ; Nordenskjöld, Bo and Rydén, Lisa LU (2009) In European Journal of Cancer 45. p.2496-2502
Abstract
BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a... (More)
BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p=0.02). In subgroup analysis the risk reduction was most pronounced in patients <40 years of age (HR 0.09, p=0.02). A risk reduction was also seen in women 40-49 years of age or >/=50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. CONCLUSION: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women <40 years of age. The effect of tamoxifen was not significantly dependent on time. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
European Journal of Cancer
volume
45
pages
2496 - 2502
publisher
IFAC & Elsevier Ltd.
external identifiers
  • wos:000270645100017
  • pmid:19535242
  • scopus:69249133380
ISSN
1879-0852
DOI
10.1016/j.ejca.2009.05.022
language
English
LU publication?
yes
id
f714f0f5-ceb9-46b9-bfb0-5352547206b3 (old id 1434183)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19535242?dopt=Abstract
date added to LUP
2009-07-06 09:13:08
date last changed
2017-09-10 04:43:57
@article{f714f0f5-ceb9-46b9-bfb0-5352547206b3,
  abstract     = {BACKGROUND: Adjuvant treatment with tamoxifen reduces the risk of contralateral breast cancer in hormone-responsive postmenopausal patients, whereas the effect in premenopausal women has not been fully elucidated. We have therefore studied the effect of tamoxifen on contralateral breast cancer in premenopausal women in a controlled randomised trial. PATIENTS AND METHODS: Premenopausal women (564) with stage II breast cancers were randomised to 2 years of tamoxifen versus control irrespective of oestrogen receptor (ER) and progesterone receptor (PgR) status. The median follow-up for patients not developing a contralateral cancer was 14 years. RESULTS: In the control group 35 women, and in the tamoxifen group 17 women, developed a contralateral breast cancer as a primary event. Tamoxifen significantly reduced the risk of contralateral breast cancer in all women regardless of age (hazard ratio (HR) 0.5, p=0.02). In subgroup analysis the risk reduction was most pronounced in patients &lt;40 years of age (HR 0.09, p=0.02). A risk reduction was also seen in women 40-49 years of age or &gt;/=50 years of age, although in these subgroups this did not reach statistical significance. The reduced risk of contralateral breast cancer was persistent during the whole follow-up time. CONCLUSION: In this randomised trial, adjuvant treatment using tamoxifen for 2 years reduced the incidence of contralateral breast cancer by 50% in all premenopausal women, and by 90% in women &lt;40 years of age. The effect of tamoxifen was not significantly dependent on time.},
  author       = {Alkner, Sara and Bendahl, Pär-Ola and Fernö, Mårten and Nordenskjöld, Bo and Rydén, Lisa},
  issn         = {1879-0852},
  language     = {eng},
  pages        = {2496--2502},
  publisher    = {IFAC & Elsevier Ltd.},
  series       = {European Journal of Cancer},
  title        = {Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.},
  url          = {http://dx.doi.org/10.1016/j.ejca.2009.05.022},
  volume       = {45},
  year         = {2009},
}